Member Info for Merchantbanker

Well they are part of the consortium part of the development project. I guess you could be right. The point i am making is ODX are not advertising their lateral flow capacity elsewhere, they are expanding to meet demand of their own products which includes the ABC-19. Hence if there was a company tendering the manufacture of 1m tests, ODX would not be a competitor of Abingdon in bidding for that business.

As i have said Wuckfit my comments here have nothing to do with another company. I see no competition. I invest based on the best risk/reward. I am "one of those" that is more concerned about facts. Hopefully there will be some on the red button tomorrow.

Speranza - goods luck for the morning, i hope it provides some much needed answers. I'm not after medals or friends.

Apologies for posted one of a few actual factual posts on here today. I don't care what you do with your tests, but they certainly are not part any government budget before they shave gone to clinical trial.

Wuckfit - yes all tests that get approved and into production will be deployed. They have 20m Innova which might last until xmas.

So your first batch of tests are going to be sent to care homes unapproved, rather than sent to LTSM for clinical trial?

There are 50 job lots being sent out to various local regions as part of the next phase of testing.

https://www.gov.uk/government/news/more-rapid-covid-19-tests-to-be-rolled-out-across-england

When talking about competitors they mention contract manufacturing. Omega are not contract manufacturers, they are manufacturing own branded products so in the context of contract manufacturing Omega are not a competitor.

Funny a lot of O's D's and X's in there!

Speranza - I am not the one making it a competition. I have said many times my view of one company has nothing to do with another. It is not my fault that the only defence posters on here can make is to attack another stock.

DOH - I didn't post on "your" board. You went and posted on a BB you have no interest in so pot kettle......

If i were you i'd be asking some questions of the company not attacking me. AS been very quiet since buying his house.

Seriously DOH - what has it got to do with ODX?

It doesn't look like PI money gone in this afternoon, so why are you bothered about a one sentence comment i made on another board without even looking into it?

Vegas i said it was one possibility, which quite frankly none of you can rule out. I also said a buy of circa £100k appeared to start the rally.
If you do get a positive RNS good for you you deserve it for having faith.

Looks like it was sparked by a 100k buy around 3:45. What i mean by that is how many people bought just because it was on the up and suspected a leak? Just one of a number of possible theories. Anyway enough about that

Dunno, not saying it's true just saying equally likely. Those with antibody tests have a hedge. It seems a little easier over there to dangle a carrot and spark some interest.

Hope for them it's news. It could equally be mms running it up short sucking mug punters in knowing a Astrazenica vaccine announcement will enable them to buy them back cheaper.

It's most likely just another "there's a test it must be ours" rally

Just a reminder the recent Omega presentation is much more useful to value Omega. Only 20% of our business is aligned to Abingdon. The other 80% is more valuable.

What still annoys me is the UK Gov are claiming credit for growing a world class diagnostics industry, but it's being built with PI money. Why have they not issued grants or interest free loans to upscale capacity?

Just because Abingdon is listing at £100m that doesn't mean that is what it's worth. Remember book builds always want a discount. If they were giving up 80% of the company and retaining 20% i'd say valuation is likely to be on the high side as they will maximise their exit price and there might be a lot of flippers. But retaining 80% means only 20% in free float and that 20% might need a more favourable deal.
I can see this doing 100%+ within a week of listing easy.

Preciousmaj - Spot on. Just because abingdon are the lead in the consortium it doesn't mean they are the bigger or better company.
Omega are already cashed up, profitable, 5 times more revenue than Abingdon, plus the core business of Omega with Food and CD4 is at the start of substantial growth. At the moment Abingdon's product hedge with their Antigen test looks like a non starter, vs Omega already producing another antibody test and an antigen test about to lift off. On par valuation undervalues Omega, despite the fact abingdon will have double the UK RTC supply, which is our lowest margin play.

I think it will be good to clear the Abingdon IPO before Mologic news. Mologic Antigen tests are more profitable so we want that upside priced in to differentiate from Abingdon. The most profitable use of our capacity would be only 200k UK RTC tests and the balance on Antigen tests.
Trilla thanks for the insight, if the details of the IPO as rumoured are true, I think low free float there can help move it very quickly.
We are now around 2 weeks from the end of lockdown, with an exit plan promised in advance. I fully expect ABC-19 and Mologic news before then.
Abingdon will be a very attractive investment prospect, but Omega will have the 2 most sought after tests on the planet. I expect we have a lot of ups and downs still to come, but as i keep saying that wont change ODX turning over millions of £s and making high margins and substantial profits. Nothing supports a share price like a strong set of results, and whatever opinions there are out there will not change the profitability.